| 摘要 |
<p>Platelet activating factor receptor antagonists of diverse structures are imparted with 5-lipoxygenase activity by adding a moiety such as a hydroxamate, hydroxyurea, oxalkane, thioalkane, quinolylmethoxy, or amidohydroxyurea to the PAF receptor antagonist at a position on the PAF antagonist molecule that demonstrates 'bulk tolerance', i.e., the ability to accommodate functionality without the significant loss of PAF activity.</p> |
